Drug Database · Clinicians

Hydrochlorothiazide + Telmisartan

Brands (63) Merit Plus, Micardis Plus, Telarb Plus…Show all

US brand (reference label): Micardis HCT; not a Philippine-registered brand.

Angiotensin 2 Receptor Blocker; Thiazide Diuretic (Angiotensin 2 Receptor Antagonists) US FDA class
Angiotensin II receptor blocker- diuretic combination; Angiotensin II receptor blocker (ARB) + diuretic,; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug101 PH productsPNF-listedPhilHealth GAMOTVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b078dae2-664d-4144-847a-3b9d9b557402, version date December 31, 2024 (Micardis HCT · Boehringer Ingelheim Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • MICARDIS HCT (telmisartan and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure.
  • MICARDIS HCT is not indicated for initial therapy
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE MICARDIS HCT (telmisartan and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs.

There are no controlled trials demonstrating risk reduction with MICARDIS HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.

For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.

The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.

Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).

These considerations may guide selection of therapy [see Clinical Studies (14)]. MICARDIS HCT is not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. MICARDIS HCT may be used alone or in combination with other antihypertensive agents. MICARDIS HCT is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1) MICARDIS HCT is not indicated for initial therapy (1)

Contraindications

4 CONTRAINDICATIONS MICARDIS HCT is contraindicated: In patients who are hypersensitive to any component of this product [see Warnings and Precautions (5.5)]. In patients with anuria. For co-administration with aliskiren in patients with diabetes [see Drug Interactions (7.4)]. Hypersensitivity to telmisartan or any component (4) Anuria (4) Co-Administration with aliskiren in patients with diabetes (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Usual starting dose is 80 mg/12.5 mg once daily (2.1)
  • Titrate up to 160 mg/25 mg as needed (2.1)
  • Initiate patients with biliary obstructive disorders or hepatic insufficiency at 40 mg/12.5 mg (2.2)
2.1 Dosing Information

2.1 Dosing Information Initiate a patient whose blood pressure is not adequately controlled with telmisartan monotherapy 80 mg on MICARDIS HCT, 80 mg/12.5 mg orally once daily. Dose can be titrated up to 160 mg/25 mg after 2 to 4 weeks, if necessary. Initiate a patient whose blood pressure is not adequately controlled by 25 mg once daily of hydrochlorothiazide, or is controlled but who experiences hypokalemia with this regimen on MICARDIS HCT 80 mg/12.5 mg once daily.

Dose can be titrated up to 160 mg/25 mg after 2 to 4 weeks, if necessary. Patients titrated to the individual components (telmisartan and hydrochlorothiazide) may instead receive the corresponding dose of MICARDIS HCT. MICARDIS HCT may be administered with other antihypertensive drugs.

2.2 Dose Adjustment for Hepatic Impairment

2.2 Dose Adjustment for Hepatic Impairment Initiate patients with biliary obstructive disorders or hepatic insufficiency under close medical supervision using the 40 mg/12.5 mg combination. MICARDIS HCT tablets are not recommended for patients with severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

2.3 Important Administration Instructions

2.3 Important Administration Instructions MICARDIS HCT tablets should not be removed from blisters until immediately before administration.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Renal Insufficiency: Telmisartan is not removed from blood by hemofiltration and is not dialyzable [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

2.2 Dose Adjustment for Hepatic Impairment Initiate patients with biliary obstructive disorders or hepatic insufficiency under close medical supervision using the 40 mg/12.5 mg combination. MICARDIS HCT tablets are not recommended for patients with severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of MICARDIS HCT in pediatric patients have not been established. Neonates with a history of in utero exposure to MICARDIS HCT: If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In the controlled clinical trials (n=1017), approximately 20% of patients treated with telmisartan/hydrochlorothiazide were 65 years of age or older, and 5% were 75 years of age or older. No overall differences in effectiveness and safety of telmisartan/hydrochlorothiazide were observed in these patients compared to younger patients.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapy.

Administration

2.3 Important Administration Instructions MICARDIS HCT tablets should not be removed from blisters until immediately before administration.

US FDA label

Dosage forms

Philippines

  • Tablet: 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg
  • Film-coated tablet: 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg
  • Uncoated bilayered tablet: 40 mg/12.5 mg, 80 mg/12.5 mg

Registered products in the Philippines

101 products registered with the Food and Drug Administration (FDA) Philippines list Hydrochlorothiazide + Telmisartan as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Telmisartan + Hydrochlorthiazide (2 products). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products101
Philippine FDA-registered products for Hydrochlorothiazide + Telmisartan
Package insert
Actarb HTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu Blister Pack x 3's x 10's Tablets (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Sun Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-4490-05
Jun 18, 2028
Actarb-HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10's tablets (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Sun Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-4489-09
Jun 18, 2028
AjezideTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets)
RxVAT-exempt
Actavis Ltd.Malta
AJ Research & Pharma, Inc.Importer: AJ Research & Pharma
DR-XY47895
Apr 4, 2027
ARB PlusTelmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg Film-Coated TabletAlu strip pack x 10's (box of 30's)
RxVAT-exempt
Corona Remedies Private LimitedIndia
Verheilen PharmaceuticalsImporter: Farma Iberica CorporationTrader: Farma Iberica S.L.
DR-XY47702
Jan 31, 2027
Emzart PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg Film-Coated TabletAlu/ALu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sandoz Grup Saglik Ürünleri Ilaçlari San. Ve Tic. A.S.Turkey
Emcure Pharma Philippines Inc.Importer: Sandoz Philippines Corporation
DRP-11408-01
Mar 10, 2027
Emzart-H 40Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
Emcure Pharma Philippines, Inc.Importer: AMB HK Enterprises, Inc.
DRP-14527-01
Oct 2, 2028
Emzart-H 80Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
Emcure Pharma Philippines, Inc.Importer: AMB HK Enterprises, Inc.
DRP-14526-01
Oct 2, 2028
IpstalTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
I.P.S. Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-4489-02
Jun 18, 2028
Merit PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletOPA/Alu/PVC-Alu blister pack x 7's (Box of 28's)
RxVAT-exempt
KRKA, D.D., Novo MestoSlovenia
Unilab, Inc.
DRP-12699
Sep 23, 2027
Merit PlusTelmisartan + Hydrochlorothiazide
40mg/12.5mg TabletAlu-Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC.
DRP-8454-01
Jun 14, 2029
Merit PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletBlister pack x 7s
RxVAT-exempt
KRKA, D.D., Novo MestoSlovenia
Unilab, Inc.
DRP-12700
Sep 23, 2027
Merit PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC.
DRP-8455-01
Jun 14, 2029
Merit PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC.
DRP-9984-01
Jun 14, 2029
Merit PlusTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu-Alu/OPA/PVC Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Krka, d. d., Novo mestoSlovenia
UNILAB, Inc.
DRP-12776
Oct 11, 2027
Mezartel-HTelmisartan + Hydrochlorothiazide
40 mg / 12.5mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2's); Alu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Macter International Ltd.Pakistan
Amson PharmaceuticalsImporter: Sahar International Trading, Inc.
DRP-7721-01
Jul 20, 2031
Micardis PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7622
Mar 17, 2029
Micardis PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Boehringer Ingelheim Hellas Single Member S.A.Greece
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-9600
Mar 25, 2031
Micardis PlusTelmisartan + Hydrochlorothiazide
80 mg / 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7621
Jul 2, 2029
Micardis PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Boehringer Ingelheim Pharma GmbH & Co. KGGermany
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7571
Mar 17, 2029
Micardis PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Boehringer Ingelheim Hellas Single Member S.A.Greece
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-9599
Mar 25, 2031
Micardis PlusTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Boehringer Ingelheim Hellas Single Member S.A.Greece
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-9598
Mar 25, 2031
Micargen PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Alternative Platform Exchange, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-8454-03
Jun 14, 2029
Micavid PlusTelmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg TabletAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Hovid Inc.Trader: Hovid Berhad
DRP-16794
Jul 11, 2030
Micavid PlusTelmisartan + Hydrochlorothiazide
80 mg/ 12.5 mg TabletAlu/Alu Blister pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Hovid Inc.Trader: Hovid Bhd.
DRP-16701
Jun 23, 2030
Misar-HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
Orange Biotec Inc.
DRP-3199
Aug 23, 2031
Mizar Plus 80Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack by 10's (Box of 30's)
RxVAT-exempt
Hiral Labs LimitedIndia
Macropharma CorporationImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-11561-01
Mar 30, 2027
Mycartan PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-8454-02
Jun 14, 2029
Mycartan PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-9984-02
Jun 14, 2029
Mycartan PlusTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.
DRP-8455-02
Jun 14, 2029
NoneTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's Box of 30's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-4489-01
Jun 18, 2028
NoneTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10 tablets (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
PharmaVital Corp.Importer: Ambica International Corporation
DRP-4489-08
Jun 18, 2028
NoneTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10 tablets (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4489-10
Jun 18, 2028
NoneTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
RITEMED PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC.
DRP-8454
Jun 14, 2029
NoneTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-4490-01
Jun 18, 2028
NoneTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
MEDINOVA PHARMACEUTICAL INC.
DRP-9984
Jun 14, 2029
NoneTelmisartan + Hydrochlorothiazide
80 mg/25 mg Film-coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Sandoz Grup Saglik Urunleri Ilaclari San. Ve. Tic. A.S.Turkey
Sandoz Philippines Corporation
DRP-9479
Jan 25, 2031
NoneTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu-Alu Blister Pack x 10's Box of 30's
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
ONESOURCE PHARMA SOLUTIONS, INC.
DRP-7911
Jul 6, 2028
NoneTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
RITEMED PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC.
DRP-8455
Jun 14, 2029
Oratel-HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
Suhitas Pharmaceuticals, Inc.Importer: Orange Biotec, Inc.
DRP-3199-04
Aug 23, 2031
Telarb PlusTelmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
The Cathay YSS Distributors Co., Inc.
DR-XY49104
Jun 3, 2029
Telarb PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
The Cathay YSS Distributors Co., Inc.Importer: Orange Biotec Inc.
DRP-3199-08
Aug 23, 2031
Telarb PlusTelmisartan + Hydrochlorothiazide
80 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
The Cathay YSS Distributors Co., Inc.
DR-XY49105
Jun 3, 2029
Telarb PlusTelmisartan + Hydrochlorothiazide
80 mg/ 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare Limited.India
The Cathay YSS Distributors Co., Inc.
DR-XY49103
Jun 3, 2029
Telatraz PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49218
Sep 20, 2029
Telatraz PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49217
Sep 20, 2029
Telatraz PlusTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alembic Pharmaceuticals LimitedIndia
Natrapharm Inc.
DR-XY49216
Sep 20, 2029
TelchorTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
Britton Distributions, Inc.Importer: Orange Biotec Inc.
DRP-3199-10
Aug 23, 2031
Telday 40 HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
TORRENT PHARMACEUTICALS LTDIndia
TORRENT PHARMA PHILIPPINES, INC.
DR-XY42407
Aug 8, 2028
Telday 80 HTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
TORRENT PHARMACEUTICALS LTD.India
TORRENT PHARMA PHILIPPINES, INC.
DR-XY42408
Aug 8, 2028
Telday H 40/12.5Telmisartan + Hydrochlorothiazide
40 mg /12.5 mg TabletAlu/Alu Blister Pack x 3's x 10 Tablets (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-4489-06
Jun 18, 2028
Telday H 80/12.5Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's x 10 Tablets (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation
DRP-4490-04
Jun 18, 2028
Telday H 80/25Telmisartan + Hydrochlorothiazide
80mg/25mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines, Inc.
DR-XY47476
Nov 16, 2026Past listed date
Teldra PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The ACME Laboratories LimitedBangladesh
Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc.
DRP-17660-01
Feb 12, 2031
Telgrand-HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc.
DRP-15318-01
Jun 18, 2029
Teli HTelmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Cadila Pharmaceuticals LimitedIndia
Ambica International Corporation
DRP-7755
Mar 21, 2028
TeliGen HCTTelmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, IncPhilippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-18266
Jun 4, 2031
Telmart DuoTelmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Macropharma CorporationImporter: Medinova Pharmaceutical Inc.
DRP-8454-04
Jun 14, 2029
Telmart DuoTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Evertogen Life Sciences LimitedIndia
Macropharma CorporationImporter: Medinova Pharmaceutical Inc.
DRP-9984-03
Jun 14, 2029
Telmart HCT 40Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Hiral Labs LimitedIndia
Macropharma CorporationImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-13271-01
Jan 17, 2028
Telmi HCTTelmisartan + Hydrochlorothiazide
40mg/12.5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY48370
Sep 22, 2027
Telmi HCTTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Importer: Ajanta Pharma Philippines Inc..
DR-XY48039
May 25, 2027
Telmibet-PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
Better Option Pharmaceuticals, Inc.Importer: Orange Biotec Inc.
DRP-3199-06
Aug 23, 2031
Telmidec-HCTTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
HLM Pharmaceutical Inc.Importer: Orange Biotec Inc.
DRP-3199-03
Aug 23, 2031
Telmidin PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's Box of 30's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Medchoice CNS Pharma CorporationImporter: Ambica International Corporation
DRP-4489-04
Jun 18, 2028
Telmifast-HTelmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ravian Life Science Pvt. Ltd.India
Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc.
DRP-15318-02
Jun 18, 2029
Telmiheart Plus 52.5Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Quad-Gen PharmaceuticalsImporter: Ambica International Corporation
DRP-4489-03
Jun 18, 2028
Telmiheart Plus 92.5Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Quad-Gen PharmaceuticalsImporter: Ambica International Corporation
DRP-4490-02
Jun 18, 2028
TELMIHYDROZET 40Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
777 RED PHARMA INC.Importer: Nelpa Lifesciences, Inc.
DRP-17421-01
Dec 19, 2030
Telmirin PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
Corbridge Group Phils., Inc.Importer: Orange Biotec Inc.
DRP-3199-05
Aug 23, 2031
Telmirx-HCTZTelmisartan/Hydrochlorothiazide
40mg/12.5mg Uncoated Bilayered TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.Trader: 20260731090220
DRP-14527
Oct 2, 2028
Telmirx-HCTZTelmisartan/Hydrochlorothiazide
80mg/12.5mg Uncoated Bilayered TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.Trader: N/A
DRP-14526
Oct 2, 2028
Telmirx-HCTZTelmisartan+Hydrochlorothiazide
80mg/25mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-14525
Oct 2, 2028
Telmisaph-80H12.5Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-17423
Dec 19, 2030
Telmisar PlusTelmisartan + Hydrochlorothiazide
40mg/12.5mg Film-Coated TabletAlu-Alu Blister Pack X 10's (Box of 30'S)
RxVAT-exempt
Mediwin Pharmaceuticals, IncIndia
Euroasia Pharmaceuticals, IncTrader: Tunic Healthcare
DRP-11014
Jun 11, 2030
Telmistal H 52.5Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10 tablets Box of 30's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-4489
Jun 18, 2028
Telmistal H 92.5Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's x 10 tablets (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-4490
Jun 18, 2028
Telmisur HCT 40Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International Inc.
DRP-17243
Oct 24, 2030
Telmisur HCT 80Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Kwality Pharmaceuticals Ltd.India
Pharma-Surrey International Inc.
DRP-17242
Oct 24, 2030
Telocar PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3’s x 10 Tablets (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Endure Medical, Inc.Importer: Ambica International Corporation
DRP-4489-07
Jun 18, 2028
Telsar HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAluminum Strip x 10's (Box of 30's)
RxVAT-exempt
Unichem Laboratories LimitedIndia
Healol Pharma Corporation
DRP-11167
Aug 29, 2028
Telsitan-HTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2's); Alu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Macter International Ltd.75700 Pakistan
Sahar International Trading Inc.
DRP-7721
Jul 20, 2031
Teltas H 12.5Telmisartan + HydrochlorthiazideVariant spelling
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited-Philippine Branch Office
DRP-10986
Dec 28, 2026
Teltas H 25Telmisartan + HydrochlorthiazideVariant spelling
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited-Philippine Branch Office
DRP-10985
Dec 28, 2026
Teluvis PlusTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sandoz Grup Saglik Ürünleri Ilaclari San. Ve Tic. A.S.Turkey
Importer: Sandoz Philippines Corporation
DRP-11409
Mar 10, 2027
Teluvis PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Sandoz Grup Saglik Ürünleri Ilaclari San. Ve Tic. A.S.Turkey
Importer: Sandoz Philippines Corporation
DRP-11408
Mar 10, 2027
TelxiblocTelmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Radbuster Inc.Importer: Ambica International Corporation
DRP-4489-05
Jun 18, 2028
Telxibloc PlusTelmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3’s x 10's (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Radbuster Inc.Importer: Ambica International Corporation
DRP-4490-03
Jun 18, 2028
Telzipar-105Telmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Alwin DMD PharmaceuticalsIndia
Aspar Pharmaceutical Inc.
DRP-18320
Jun 11, 2031
Telzyd H 40/12.5Telmisartan + Hydrochlorothiazide
40 mg / 12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Theon Pharmaceuticals Ltd.India
Zydus Healthcare Philippines, Inc.Importer: Orange Biotec Inc.
DRP-3199-02
Aug 23, 2031
Temtan-H 40Telmisartan + Hydrochlorothiazide
40 mg/ 12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Hiral Labs LimitedIndia
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-13271
Jan 17, 2028
Temtan-H 80Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
RxVAT-exempt
Hiral Labs LimitedIndia
Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-11561
Mar 30, 2032
Tevex TH 80/12.5Telmisartan + Hydrochlorothiazide
80 mg/12.5 TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
East African (India) OverseasIndia
Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY49427
Jun 27, 2030
Trelauro-H 40/12.5Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Aurobindo Pharma Limited - Unit VIIIndia
AAA Pharma, Inc.
DR-XY49559
Oct 20, 2030
Trelauro-H 80/12.5Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Aurobindo Pharma Limited Unit VIIIndia
AAA Pharma, Inc.
DR-XY49575
Nov 7, 2030
Trelauro-H 80/25Telmisartan + Hydrochlorothiazide
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Aurobindo Pharma Limited - Unit VIIIndia
AAA Pharma, Inc.
DR-XY49558
Oct 20, 2030
Tsartan PlusTelmisartan + Hydrochlorothiazide
40mg/12.5mg TabletAlu-Alu Blister Pack x 10's (Box of 30' s)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Orange Biotec Inc.
DRP-14147
Jun 30, 2028
Tsartan PlusTelmisartan + Hydrochlorothiazide
80mg/12.5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Orange Biotec Inc.
DRP-14236
Aug 1, 2028
Tsartan PlusTelmisartan + Hydrochlorothiazide
80mg/25mg TabletAlu-Alu Blister Pack x 10' s (Box of 30' s)
RxVAT-exempt
Inventia Healthcare LimitedIndia
Orange Biotec Inc.
DRP-14146
Jun 30, 2028
(no brand name)Telmisartan + Hydrochlorothiazide
40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Onesource Pharma Solutions, Inc.
DRP-14139
Jun 30, 2028
(no brand name)Telmisartan + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
The Acme Laboratories LimitedBangladesh
Euro Generics International Phils., Inc.
DR-XY49576
Nov 17, 2030
(no brand name)Telmisartan + + Hydrochlorothiazide
80 mg/12.5 mg TabletAlu-Alu Blister Pack x 10s (Box of 30's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Onesource Pharma Solutions, Inc.
DRP-16870
Aug 1, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 40 mg/12.5 mg, red and white tablets marked with the Boehringer Ingelheim logo and "H4" 80 mg/12.5 mg, red and white tablets marked with the Boehringer Ingelheim logo and "H8" 80 mg/25 mg, yellow and white tablets marked with the Boehringer Ingelheim logo and "H9" Tablets: 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Avoid fetal or neonatal exposure (5.1)
  • Correct volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension. (5.2)
  • Monitor renal function and potassium in susceptible patients (5.3)
  • Observe for clinical signs of fluid or electrolyte imbalance (5.4)
  • Hypersensitivity Reaction (5.5)
  • Acute Myopia and Secondary Angle-Closure Glaucoma (5.6)
5.1 Fetal Toxicity

5.1 Fetal Toxicity Telmisartan Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. Hydrochlorothiazide Thiazides cross the placental barrier and appear in cord blood. Adverse reactions include fetal or neonatal jaundice and thrombocytopenia [see Use in Specific Populations (8.1)].

5.2 Hypotension in Volume- or Salt-Depleted Patients

5.2 Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with MICARDIS HCT. Correct volume or salt depletion prior to administration of MICARDIS HCT.

5.3 Impaired Renal Function

5.3 Impaired Renal Function Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing oliguria, progressive azotemia, or acute renal failure on MICARDIS HCT.

Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on MICARDIS HCT.

5.4 Electrolytes and Metabolic Disorders

5.4 Electrolytes and Metabolic Disorders Drugs, including telmisartan, that inhibit the renin-angiotensin system can cause hyperkalemia, particularly in patients with renal insufficiency, diabetes, or combination use with other angiotensin receptor blockers or ACE inhibitors and the concomitant use of other drugs that raise serum potassium levels [see Drug Interactions (7.1, 7.4)]. Hydrochlorothiazide can cause hypokalemia and hyponatremia.

Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Hypomagnesemia can result in hypokalemia which may be difficult to treat despite potassium repletion. Monitor serum electrolytes periodically. In controlled trials using the telmisartan/hydrochlorothiazide combination treatment, no patient administered 40 mg/12.5 mg, 80 mg/12.5 mg, or 80 mg/25 mg experienced a decrease in potassium ≥1.4 mEq/L, and no patient experienced hyperkalemia.

Hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium. Hydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglycerides. Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy. Because telmisartan decreases uric acid, telmisartan in combination with hydrochlorothiazide attenuates the diuretic-induced hyperuricemia.

5.5 Hypersensitivity Reaction

5.5 Hypersensitivity Reaction Hydrochlorothiazide Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history [see Contraindications (4)].

5.6 Acute Myopia and Secondary Angle-Closure Glaucoma

5.6 Acute Myopia and Secondary Angle-Closure Glaucoma Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.

Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.

5.7 Systemic Lupus Erythematosus

5.7 Systemic Lupus Erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.

5.8 Postsympathectomy Patients

5.8 Postsympathectomy Patients The antihypertensive effects of hydrochlorothiazide may be enhanced in the postsympathectomy patient.

Drug interactions

Drug interactions (US label) US FDA label
  • Lithium: Risk of lithium toxicity (7.2)
  • Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; increased risk of renal impairment (7.3)
  • Dual blockade of renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.4)
  • Antidiabetic drugs: Dosage adjustment may be required (7.6)
  • Cholestyramine and colestipol: Reduced absorption of thiazides (7.7)
7.1 Agents Increasing Serum Potassium

7.1 Agents Increasing Serum Potassium Co-administration of telmisartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.

7.2 Lithium

7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of thiazide diuretics or angiotensin II receptor antagonists, including telmisartan. Monitor lithium levels in patients receiving MICARDIS HCT and lithium.

7.3 Non-Steroidal Anti-Inflammatory

7.3 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors Telmisartan Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ARBs, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.

The antihypertensive effect of ARBs may be attenuated by NSAIDs. Therefore, monitor renal function and blood pressure periodically in patients receiving MICARDIS HCT and NSAIDs. Hydrochlorothiazide Administration of a non-steroidal anti-inflammatory agent, including a selective COX-2 inhibitor, can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics.

Therefore, when MICARDIS HCT and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.

7.4 Dual Blockade of the Renin-Angiotensin-Aldosterone System and Changes in Renal Function

7.4 Dual Blockade of the Renin-Angiotensin-Aldosterone System and Changes in Renal Function Dual blockade of the renin-angiotensin-aldosterone system (RAS) with angiotensin blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and renal impairment. The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomizing them to telmisartan (ARB) only, ramipril (ACE inhibitor) only, or the combination, and followed them for a median of 56 months.

Patients who received the combination of ARB and ACE inhibitor did not obtain any additional benefit (no additional reduction of risk of cardiovascular death, myocardial infarction, stroke, or hospitalization from heart failure) compared to ARB monotherapy or ACE inhibitor monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with monotherapy groups. In general, avoid combined use of RAS inhibitors.

Closely monitor blood pressure, renal function and electrolytes in patients on MICARDIS HCT and other agents that affect the RAS. Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes. Avoid concomitant use of aliskiren with MICARDIS HCT in patients with renal impairment (GFR <60 mL/min/1.73 m²).

7.5 Digoxin

7.5 Digoxin When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Monitor digoxin levels in patients taking concomitant MICARDIS HCT and digoxin.

7.6 Antidiabetic Drugs (Oral Agents and Insulin)

7.6 Antidiabetic Drugs (Oral Agents and Insulin) Dosage adjustment of antidiabetic drugs may be required when co-administered with hydrochlorothiazide.

7.7 Cholestyramine and Colestipol Resins

7.7 Cholestyramine and Colestipol Resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Stagger the dosage of hydrochlorothiazide and the resin such that hydrochlorothiazide is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.

Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed elsewhere in labeling: Hypotension [see Warnings and Precautions (5.2)] Renal Impairment [see Warnings and Precautions (5.3)] Electrolytes and Metabolic Disorders [see Warnings and Precautions (5.4)] The most common adverse reactions (≥2% of patients) were upper respiratory tract infection, dizziness, sinusitis, diarrhea, fatigue, influenza-like symptoms, and nausea (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. MICARDIS HCT has been evaluated for safety in more than 1700 patients, including 716 treated for hypertension for longer than 6 months and 420 for more than 1 year.

Adverse reactions have been limited to those that have been previously reported with telmisartan and/or hydrochlorothiazide. Adverse reactions occurring at an incidence of ≥2% in patients treated with telmisartan/hydrochlorothiazide and at a greater rate than in patients treated with placebo, are presented in Table 1 [see Clinical Studies (14)].

Table 1 Adverse Reactions Occurring at an Incidence of ≥2% in Patients Treated with Telmisartan/Hydrochlorothiazide and at a Greater Rate Than in Patients Treated with Placebo* * includes all doses of telmisartan (20 to 160 mg), hydrochlorothiazide (6.25 to 25 mg), and combinations thereof Telmisartan/Hydrochlorothiazide (n = 414) Placebo (n = 74) Telmisartan (n = 209) Hydrochlorothiazide (n = 121) Body as a whole Fatigue 3% 1% 3% 3% Influenza-like symptoms 2% 1% 2% 3% Central/Peripheral nervous system Dizziness 5% 1% 4% 6% Gastrointestinal system Diarrhea 3% 0% 5% 2% Nausea 2% 0% 1% 2% Respiratory system disorder Sinusitis 4% 3% 3% 6% Upper respiratory tract infection 8% 7% 7% 10% Other adverse reactions observed for telmisartan/hydrochlorothiazide were: pain (including back and abdominal), dyspepsia, erythema, vomiting, bronchitis, and pharyngitis. Adverse reactions occurred at approximately the same rates in men and women, older and younger patients, and black and non-black patients.

Telmisartan Other adverse events that have been reported with telmisartan are listed below: Autonomic Nervous System: impotence, increased sweating, flushing Body as a Whole: allergy, fever, leg pain, chest pain Cardiovascular: palpitation, angina pectoris, abnormal ECG, hypertension, peripheral edema Central Nervous System: insomnia, somnolence, migraine, paresthesia, involuntary muscle contractions, hypoesthesia Gastrointestinal: flatulence, constipation, gastritis, dry mouth, hemorrhoids, gastroesophageal reflux, toothache Hepato-biliary: elevations of liver enzymes or serum bilirubin Metabolic: gout, hypercholesterolemia, diabetes mellitus Musculoskeletal: arthritis, arthralgia, leg cramps, myalgia Psychiatric: anxiety, depression, nervousness Resistance Mechanism: infection, abscess, otitis media Respiratory: asthma, rhinitis, dyspnea, epistaxis Skin: dermatitis, eczema, pruritus Urinary: micturition frequency, cystitis Vascular: cerebrovascular disorder Special Senses: abnormal vision, conjunctivitis, tinnitus, earache Hydrochlorothiazide Other adverse events that have been reported with hydrochlorothiazide are listed below: Body as a Whole: weakness Digestive: pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation Hematologic: aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia Hypersensitivity: purpura, photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions Metabolic: hyperglycemia, glycosuria Musculoskeletal: muscle spasm Nervous System/Psychiatric: restlessness Renal: interstitial nephritis Skin: erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis Special Senses: transient blurred vision, xanthopsia Clinical Laboratory Findings Creatinine, Blood Urea Nitrogen (BUN): Increases in BUN (≥11.2 mg/dL) and serum creatinine (≥0.5 mg/dL) were observed in 2.8% and 1.4%, respectively, of patients with essential hypertension treated with MICARDIS HCT tablets in controlled trials. No patient discontinued treatment with MICARDIS HCT tablets because of an increase in BUN or creatinine [see Warnings and Precautions (5.3)].

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of MICARDIS HCT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.

Blood and Lymphatic System Disorders: Eosinophilia Cardiac Disorders: Tachycardia Ear and Labyrinth Disorders: Vertigo General Disorders and Administration Site Conditions: Asthenia, edema Hepato-biliary: Abnormal hepatic function/liver disorder Immune System Disorders: Anaphylactic reaction Investigations: Increased CPK Metabolism and Nutrition Disorders: Hypoglycemia (in diabetic patients), hyponatremia Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis Nervous System Disorders: Headache, syncope Renal and Urinary Disorders: Renal failure, renal impairment including acute renal failure Reproductive System and Breast Disorders: Erectile dysfunction Respiratory, Thoracic and Mediastinal Disorders: Coughing Skin and Subcutaneous Tissue Disorders: Angioedema (with fatal outcome), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria) Vascular Disorder: Orthostatic hypotension Non-melanoma Skin Cancer Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses.

The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.

Adverse reaction frequency tables (US label) US FDA label
Table 1 Adverse Reactions Occurring at an Incidence of ≥2% in Patients Treated with Telmisartan/Hydrochlorothiazide and at a Greater Rate Than in Patients Treated with Placebo*
* includes all doses of telmisartan (20 to 160 mg), hydrochlorothiazide (6.25 to 25 mg), and combinations thereof
Telmisartan/Hydrochlorothiazide (n = 414)Placebo (n = 74)Telmisartan (n = 209)Hydrochlorothiazide (n = 121)
Body as a whole
Fatigue3%1%3%3%
Influenza-like symptoms2%1%2%3%
Central/Peripheral nervous system Dizziness 5%1%4%6%
Gastrointestinal system
Diarrhea3%0%5%2%
Nausea2%0%1%2%
Respiratory system disorder Sinusitis 4%3%3%6%
Upper respiratory tract infection8%7%7%10%

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary MICARDIS HCT can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see Clinical Considerations). Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.

Studies in rats and rabbits with telmisartan showed fetotoxicity only at maternally toxic doses (see Data). When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).

Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Telmisartan Use of drugs that act on the RAS in the second and third trimesters of pregnancy can result in the following: oligohydramnios, reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. In patients taking MICARDIS HCT during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment.

Fetal testing may be appropriate, based on the week of gestation. If oligohydramnios is observed, discontinue MICARDIS HCT, unless it is considered lifesaving for the mother. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to MICARDIS HCT for hypotension, oliguria, and hyperkalemia.

If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function [see Use in Specific Populations (8.4)]. Hydrochlorothiazide Thiazides cross the placenta, and use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults.

Data Animal Data MICARDIS HCT A developmental toxicity study was performed in rats with telmisartan/hydrochlorothiazide doses of 3.2/1.0, 15/4.7, 50/15.6, and 0/15.6 mg/kg/day. Although the two higher dose combinations appeared to be more toxic (significant decrease in body weight gain) to the dams than either drug alone, there did not appear to be an increase in toxicity to the developing embryos.

Telmisartan No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses of up to 45 mg/kg/day. In rabbits, embryo lethality associated with maternal toxicity (reduced body weight gain and food consumption) was observed at 45 mg/kg/day (approximately 12 times the maximum recommended human dose [MRHD] of 80 mg on a mg/m 2 basis).

In rats, maternally toxic (reduced body weight gain and food consumption) telmisartan doses of 15 mg/kg/day (approximately 1.9 times the MRHD on a mg/m 2 basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, and decreased weight gain. The no-observed-effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are approximately 0.64 and 3.7 times, respectively, on a mg/m 2 basis, the MRHD of telmisartan (80 mg/day).

Hydrochlorothiazide Studies in which hydrochlorothiazide was administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg/kg/day, respectively (about 600 and 400 times the MRHD), provided no evidence of harm to the fetus. Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma.

Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion. It accumulates in the amniotic fluid, with reported concentrations up to 19 times that in umbilical vein plasma. Use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice or thrombocytopenia. Since they do not prevent or alter the course of EPH (Edema, Proteinuria, Hypertension) gestosis (pre-eclampsia), these drugs should not be used to treat hypertension in pregnant women.

The use of hydrochlorothiazide for other indications (e.g., heart disease) in pregnancy should be avoided.

Mechanism of action

12.1 Mechanism of Action MICARDIS HCT MICARDIS HCT is a combination of two drugs with antihypertensive properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin II receptor blocker (ARB), telmisartan. Telmisartan Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).

Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.

Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT 2 receptor found in many tissues, but AT 2 is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (>3,000-fold) for the AT 1 receptor than for the AT 2 receptor. Telmisartan does not inhibit ACE (kininase II) nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.

Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure. Hydrochlorothiazide Hydrochlorothiazide is a thiazide diuretic.

Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium salt and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.

The renin-aldosterone link is mediated by angiotensin II, so co-administration of an ARB tends to reverse the potassium loss associated with these diuretics. The mechanism of the antihypertensive effect of thiazides is not fully understood.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Telmisartan In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by approximately 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours. Plasma concentration of angiotensin II and plasma renin activity increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients.

The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium) or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid).

The antihypertensive effects of telmisartan have been studied in six placebo-controlled clinical trials including a total of 1773 patients with mild to moderate hypertension (diastolic blood pressure of 95 to 114 mmHg), 1031 of whom were treated with telmisartan. Following once-daily administration of telmisartan, the magnitude of blood pressure reduction from baseline after placebo subtraction was approximately (SBP/DBP) 6-8/6 mmHg for 20 mg, 9-13/6-8 mmHg for 40 mg, and 12-13/7-8 mmHg for 80 mg.

Larger doses (up to 160 mg) did not appear to cause a further decrease in blood pressure. The onset of antihypertensive activity occurs within 3 hours, with a maximal reduction by approximately 4 weeks. At doses of 20, 40, and 80 mg, the antihypertensive effect of once-daily administration of telmisartan was maintained for the full 24-hour dose interval.

In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. Hydrochlorothiazide After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours, and lasts approximately 6 to 12 hours.

Drug Interactions Hydrochlorothiazide Alcohol, barbiturates, or narcotics: Potentiation of orthostatic hypotension may occur. Skeletal muscle relaxants: Possible increased responsiveness to muscle relaxants such as curare derivatives. Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.

Elimination: Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).

Terminal half-life and total clearance appear to be independent of dose.

When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.

Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Telmisartan Absorption: Following oral administration, peak concentrations (C max) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of approximately 6% with 40 mg and approximately 20% after a 160 mg dose.

MICARDIS HCT can be administered with or without food. The absolute bioavailability of telmisartan is dose dependent. At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively. The pharmacokinetics of telmisartan with orally administered MICARDIS are nonlinear over the dose range 20 mg to 160 mg, with greater than proportional increases of plasma concentrations (C max and AUC) with increasing doses.

Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. Trough plasma concentrations of telmisartan with once-daily dosing are approximately 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once-daily dosing.

Distribution: Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters, indicating additional tissue binding. Metabolism: Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine.

After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan. Elimination: Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).

Total plasma clearance of telmisartan is >800 mL/min. Terminal half-life and total clearance appear to be independent of dose. Hydrochlorothiazide Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.

At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. Specific Populations Telmisartan Renal Insufficiency: Telmisartan is not removed from blood by hemofiltration and is not dialyzable [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)].

Hepatic Insufficiency: In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% [see Use in Specific Populations (8.6)]. Gender: Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women.

No dosage adjustment is necessary. Geriatric Patients: The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years of age. Drug Interaction Studies Telmisartan Ramipril: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state C max and AUC of ramipril 2.3- and 2.1-fold, respectively, and C max and AUC of ramiprilat 2.4- and 1.5-fold, respectively.

In contrast, C max and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.

Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.

Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet₱19.02–₱23.15Reference ₱19.02per tabletDPRI procurement range
40 mg + 12.5 mg tablet₱11.75per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Telmisartan + Hydrochlorothiazide
PNF listingOral: 40 mg + 12.5 mg tablet
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Micardis HCT · Boehringer Ingelheim Pharmaceuticals, Inc. [US FDA-approved label, version 26, December 31, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b078dae2-664d-4144-847a-3b9d9b557402
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .